Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 846 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hyperlipemia Clear all
Recruiting Phase 1 Interventional

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT07491172
View directory record Official record
Conditions
Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia
Interventions
CTX310
Drug
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Hialeah, Florida • Jacksonville, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 2 Interventional Results available

Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

NCT06640972
View directory record Official record
Conditions
Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
Interventions
RDX-002, Placebo
Drug
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 2Phase 3 Interventional

MARS - Monitored Atherosclerosis Regression Study

NCT00116870
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
lovastatin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
21 Years to 67 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 1992
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Not applicable Interventional

Low-Carbohydrate and Plant-Based Dietary Effects on Vascular Health

NCT05414851
View directory record Official record
Conditions
Heart Disease, Ischemic, Hyperlipidemias, Hypertension
Interventions
Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet
Other
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Webster, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 4 Interventional

SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia

NCT00194402
View directory record Official record
Conditions
Dyslipidemia
Interventions
Slo-Niacin, atorvastatin
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 4 Interventional Results available

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

NCT05742841
View directory record Official record
Conditions
Lipid Disorder
Interventions
moderate- or high-intensity statin/ rosuvastatin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 1 Interventional

The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia

NCT01308710
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Omega-3 fatty acid (Eicosapentaenoic acid)
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
8 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 2 Interventional

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

NCT01279590
View directory record Official record
Conditions
Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions
PPD10558, Atorvastatin, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
67
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2011 · Synced Oct 23, 2026, 7:31 AM EDT
Withdrawn Phase 2 Interventional

Study of MB07811 in Subjects With Hypercholesterolemia

NCT00879112
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MB07811, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
11
States / cities
San Diego, California • Jacksonville, Florida • Pembroke Pines, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 23, 2026, 7:31 AM EDT
Not listed No phase listed Observational

Study of Awareness and Detection of Familial Hypercholesterolemia

NCT01960244
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Not listed
Lead sponsor
The Familial Hypercholesterolemia Foundation
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 4 Interventional Results available

Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study

NCT01409434
View directory record Official record
Conditions
Drug Induced Hyperglycemia, Secondary Hyperlipidemia
Interventions
Oral Glucose Tolerance Test
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

NCT03847974
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
LIB003
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 3 Interventional Results available

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

NCT01813422
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
59
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study Testing Feasibility of Health Screening at Farm Site

NCT02418637
View directory record Official record
Conditions
Diabetes Screening, Hyperlipidemia Screening, Hypertension Screening
Interventions
Worksite screening for DM, HTN and hyperlipidemia
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 2 Interventional Results available

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT02890992
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

NCT05934292
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Enlicitide Decanoate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Hallandale, Florida • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 7:31 AM EDT
Withdrawn No phase listed Observational

Genetic Influence on Statin Pharmacodynamics

NCT01569854
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

NCT03385239
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Diseases
Interventions
ISIS 678354, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 23, 2026, 7:31 AM EDT
Completed No phase listed Observational

Genetic Influences on Statin Blood Concentrations in African Americans

NCT01569867
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 23, 2026, 7:31 AM EDT
Completed No phase listed Observational

Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis

NCT01592084
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 23, 2026, 7:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Change in Diet May Decrease the Negative Consequences of Chronic Sleep Deprivation

NCT00123214
View directory record Official record
Conditions
Sleep Deprivation
Interventions
Controlled Dietary Intervention
Drug
Lead sponsor
St. Vincent's Medical Center
Other
Eligibility
25 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2006 · Synced Oct 23, 2026, 7:31 AM EDT
Withdrawn Phase 4 Interventional

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

NCT01180764
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza (Omega-3 acid ethyl esters), Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 23, 2026, 7:31 AM EDT